A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.
Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...
DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...
A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...
Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...
Galleri is a blood test that aims to detect over 50 types of cancer early. It analyzes cell-free DNA (cfDNA) and methylation patterns to identify potential cancer signals. The test is intended for ...
3don MSN
The one test that can prevent your risk of Cancer, according to top doctor and longevity expert
The treatment success rate for cancer patients improves when doctors detect the disease during its initial stages, because ...
A new cfDNA-based blood test uses AI to detect bladder, prostate, and kidney cancers early, offering a faster, safer, and ...
An Austin, Texas-based genetics-testing company that specializes in cell-free DNA and precision medicine has acquired Foresight Diagnostics Inc., a Boulder-based cancer-diagnostics company.
*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback